GLP-1 injury liability could top $2 billion as federal lawsuits pass 4,000, analysts estimate
Analysts put potential liability above $2 billion across two GLP-1 injury cases, but no trial has been held and mass settlements are not expected before late 2027.
Legal analysts estimate that combined liability across the two federal GLP-1 injury cases could exceed $2 billion, according to MDL Update, which tracks the litigation [1]. No case has gone to trial in either case, and no settlements have been announced [1].
The estimate covers two separate consolidated cases before Judge Karen S. Marston in the Eastern District of Pennsylvania. MDL 3094, created in February 2024, handles gastrointestinal claims such as gastroparesis, ileus and intestinal obstruction [1]. MDL 3163, created in December 2025, handles a form of vision loss called non-arteritic anterior ischemic optic neuropathy, or NAION [1]. Both name Novo Nordisk and Eli Lilly as defendants. The drugs involved include Ozempic, Wegovy and Rybelsus, all semaglutide, and Mounjaro and Zepbound, both tirzepatide, among others [1].
MDL 3094 had 4,022 pending actions as of September 2026, out of 4,056 total filed, a 202% increase since January 2025 [1]. About 75% of complaints allege gastroparesis, also called stomach paralysis, 18% allege ileus and 8% allege gallbladder injuries [1]. MDL 3163 had about 200 cases as of September 2026 [1]. It grew from roughly 30 cases when it was created to more than 130 by early July 2026, according to one law firm's litigation timeline [2]. That firm reports 146 cases in that MDL as of July 6, 2026 [2].
The $2 billion figure is an estimate of potential exposure, not money awarded or paid. A viral video in late August 2026 also claimed that related litigation could be worth billions, but the claims in that video had not been independently verified and no specific $2 billion lawsuit or settlement matching that description had been confirmed in court filings [2].
On the regulatory side, the FDA updated the Ozempic label in October 2025 to say the drug "is not recommended in patients with severe gastroparesis" [1]. U.S. labels for Ozempic, Wegovy and Rybelsus still contain no NAION warning, while the European Medicines Agency's Pharmacovigilance Risk Assessment Committee concluded in June 2025 that NAION is a rare but real side effect of semaglutide and recommended adding it to European labeling [2].
Why it matters for patients
An estimated liability figure does not mean any patient has been paid, and it does not establish that any drug caused any specific injury. No trial has tested these claims yet [1]. What such estimates typically reflect is how much money analysts think the companies might eventually pay to resolve thousands of claims, which can influence how willing the manufacturers are to settle and how much they set aside.
For people currently taking semaglutide or tirzepatide, nothing in the litigation record changes the approved labeling, which already describes delayed stomach emptying as part of how the drugs work and warns about ileus, intestinal obstruction and pancreatitis [1]. Judge Marston has required objective diagnostic testing for gastroparesis claims, and diagnosis generally requires a gastric emptying study showing more than 10% retention at four hours [1]. Not everyone who files a claim has that documentation.
What happens next
Daubert motions were due April 28, 2026, and summary judgment briefing ran through July 2026 [1]. Bellwether trial selection was expected around mid-2026, with the first trials possible in late 2026 [1]. One litigation tracker describes bellwether trials as anticipated for late 2026 or 2027 [2]. Mass settlements are considered unlikely before late 2027 [1]. No trial dates, settlement amounts or total damages have been disclosed.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.